StockNews.AI
TEM
StockNews.AI
5 days

TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating Tempus for potential investor claims. 2. Class action complaint filed alleges fiduciary duty breaches by Tempus board. 3. Concerns include inflated contract values and unsustainable billing practices. 4. Stock price dropped 19.23% following negative report on company management. 5. Investors encouraged to contact law firm for rights and options.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price (19.23%) indicates a severe loss of investor confidence. Historical precedents show similar lawsuits often lead to sustained declines for involved companies.

How important is it?

The article discusses serious allegations against Tempus that could impact its operations and stock value. Given the nature of the claims, the investor sentiment is likely to be highly affected.

Why Long Term?

Ongoing investigations and potential legal ramifications can lead to prolonged negative sentiment. Companies with similar legal issues have faced extended periods of recovery.

Related Companies

AstraZenecaSoftBank
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Tempus between August 6, 2024 and May 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tempus AI, Inc. (NASDAQ:TEM) on behalf of long-term stockholders following a class action complaint that was filed against Tempus on June 12, 2025 with a Class Period from August 6, 2024 and May 27, 2025. Our investigation concerns whether the board of directors of Tempus have breached their fiduciary duties to the company. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of "round-tripping" capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. If you are a long-term stockholder of Tempus, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News